Global phase 2 data in TNBC look similar to earlier results in China.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
The first TUB-040 data come just after Tubulis raised €308m.
Full data from Edge-Gastric are presented at ESMO.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
